Acrivon Therapeutics Inc
NASDAQ:ACRV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acrivon Therapeutics Inc
Depreciation & Amortization
Acrivon Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acrivon Therapeutics Inc
NASDAQ:ACRV
|
Depreciation & Amortization
$1.4m
|
CAGR 3-Years
56%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$209.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$543.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
22%
|
|
Acrivon Therapeutics Inc
Glance View
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2022-11-15. The firm's lead clinical candidate ACR-368, is a selective small molecule inhibitor targeting CHK1/2. CHK1/2 are regulators of the cell cycle and of DNA Damage Response (DDR). The company also has two preclinical drug programs designed to take advantage of its AP3 platform and the ability to predict tumor sensitivity based on custom OncoSignature tests. Its AP3 platform is based on its proprietary approach developed to enable treatment of the patients who are most likely to respond to any particular drug candidate based on dependency in the tumor on the upregulated specific biochemical pathways that each drug modulates. The firm's OncoSignature tests are automated, quantitative proteomic tissue imaging tests applied to pre-treatment tumor biopsies as a companion diagnostic (CDx), to select and treat the patients predicted to benefit from the drug candidate.
See Also
What is Acrivon Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
1.4m
USD
Based on the financial report for Dec 31, 2025, Acrivon Therapeutics Inc's Depreciation & Amortization amounts to 1.4m USD.
What is Acrivon Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
167%
Over the last year, the Depreciation & Amortization growth was 35%. The average annual Depreciation & Amortization growth rates for Acrivon Therapeutics Inc have been 56% over the past three years , 167% over the past five years .
